(NASDAQ: STRO) Sutro Biopharma's forecast annual revenue growth rate of 7.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.15%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.71%.
Sutro Biopharma's revenue in 2025 is $66,434,000.On average, 5 Wall Street analysts forecast STRO's revenue for 2025 to be $8,156,518,479, with the lowest STRO revenue forecast at $7,297,377,475, and the highest STRO revenue forecast at $9,387,036,106. On average, 4 Wall Street analysts forecast STRO's revenue for 2026 to be $5,913,815,855, with the lowest STRO revenue forecast at $844,613,650, and the highest STRO revenue forecast at $9,856,641,296.
In 2027, STRO is forecast to generate $8,416,575,022 in revenue, with the lowest revenue forecast at $6,483,254,377 and the highest revenue forecast at $10,349,895,667.